DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

BLA 125427/S-096

SUPPLEMENT APPROVAL

Genentech, Inc.
Attention: Monica Shah
Regulatory Program Management
1 DNA Way, MS# 242
South San Francisco, CA 94080-4990

Dear Ms. Shah:

Please refer to your Supplemental Biologics License Application (sBLA), dated February 15, 2016, received February 16, 2016, submitted under section 351(a) of the Public Health Service Act for Kadcyla® (ado-trastuzumab emtansine).

This Prior Approval supplemental biologics application provides for updates to the Kadcyla® US Package Insert to include a recommendations for appropriate use of Kadcyla® in patients with hepatic impairment. This recommendation is supported by the final clinical study report for Study BO25499 entitled, *"A Phase I, open label, parallel group, pharmacokinetic study of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and normal or reduced hepatic function"*.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Rajesh Venugopal, Senior Regulatory Project Manager, at (301) 796-4730.

Sincerely,
{See appended electronic signature page}

Geoffrey Kim, MD
Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

GEOFFREY S KIM
07/25/2016